Dilek SOLMAZ, Servet AKAR, Özgül SOYSAL, Nurullah AKKOÇ, Sülen SARIOĞLU, Vedat GERDAN, Gökçe KENAR, Fatoş ÖNEN, Gerçek CAN, Merih BİRLİK

The prevalence of Sjögren’s syndrome and sicca symptoms in patients with systemic sclerosis and alpha-smooth muscle actin expression in biopsy specimens from minor salivary glands

Background/aim: This study aimed to investigate the prevalence of sicca symptoms and secondary Sjögren’s syndrome (SjS) in patients with systemic sclerosis (SSc). Also this study aimed to evaluate the expression of α-smooth muscle actin (α–SMA) in minor salivary gland (MSG) specimens, a possible marker of fibrosis responsible for myofibroblastic transformation. Materials and methods: Patients with SSc who were followed in Rheumatology outpatient clinic at a university hospital evaluated. The questionnaire of sicca symptoms and classification of SjS were evaluated according to the American–European Consensus Group (AECG) criteria. Histopathologic evaluations were done in MSG specimens investigating the presence of focal lymphocytic sialadenitis and glandular fibrosis, also assessing the expression of α–SMA. Results: This cross-sectional study included 102 patients with SSc [91 females (89%), mean age 52.5 ± 12 years]. In this cohort 76 (75%) patients had sicca symptoms and 36 (35.3%) patients fulfilled the AECG criteria for SjS; all with limited form. Having SjS found to be associated with older age and the presence of positive anti-SS-A antibodies. On histopathologic examinations, glandular fibrosis was observed in 67 (80%) and lymphocytic sialadenitis was detected in 38 (45%) patients; but only 7 samples were positive for α–SMA. Conclusion: This study suggested sicca symptoms were found to be very common among patients with SSc. Also secondary SjS was detected in nearly one-third of patients with SSc; especially in limited subtype. Anti SS-A positivity and older age were detected as predictors for SjS. Histopathologic evaluations showed significant glandular fibrosis but rare α-SMA staining in patients with SSc.Key words: Fibrosis, scleroderma, sicca, Sjögren’s syndrome, alpha-SMA

PDF

___

1. Allanore Y, Simms R, Distler O, Trojanowska M, Pope J et al. Systemic sclerosis. Nature Reviews Disease Primers 2015; 23;1:15002. doi: 10.1038/nrdp.2015.2
2. Alarcon-Segovia D, Ibanez G, Hernandez-Ortiz J, VelazquezForero F, Gonzalez-Jimenez Y. Sjogren’s syndrome in progressive systemic sclerosis (scleroderma). The American Journal of Medicine 1974; 57 (1): 78-85. doi: 10.1016/0002- 9343(74)90771-2
3. Salliot C, Mouthon L, Ardizzone M, Sibilia J, Guillevin L et al. Sjogren’s syndrome is associated with and not secondary to systemic sclerosis. Rheumatology (Oxford) 2007; 46 (2): 321- 326. doi: 10.1093/rheumatology/kel252
4. Avouac J, Sordet C, Depinay C, Ardizonne M, Vacher-Lavenu MC et al. Systemic sclerosis-associated Sjogren’s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis & Rheumatology 2006; 54 (7): 2243-2249. doi: 10.1002/art.21922
5. Varga JA, Trojanowska M. Fibrosis in systemic sclerosis. Rheumatic Disease Clinics of North America 2008; 34 (1): 115-143; vii.
6. Rajkumar VS, Howell K, Csiszar K, Denton CP, Black CM et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Research and Therapy 2005; 7 (5): R1113-1123. doi: 10.1186/ar1790
7. Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Research and Therapy 2007; 9 Suppl 2:S4. doi: 10.1186/ar2188
8. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Annals of Rheumatic Diseases 2002; 61 (6): 554-558. doi: 10.1136/ard.61.6.554
9. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis & Rheumatology 1980; 23 (5): 581-590. doi: 10.1002/art.1780230510
10. LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. Journal of Rheumatology 2001; 28 (7): 1573-1576.
11. Lemp MA. Report of the national eye ınstitute/ındustry workshop on clinical trials in dry eyes. The CLAO Journal 1995; 21 (4): 221-232.
12. Fox PC, Brennan M, Pillemer S, Radfar L, Yamano S et al. Sjogren’s syndrome: a model for dental care in the 21st century. The Journal of American Dental Association 1998; 129 (6): 719-728. doi: 10.14219/jada.archive.1998.0313
13. Daniels TE, Cox D, Shiboski CH, Schiodt M, Wu A et al. Associations between salivary gland histopathologic diagnoses and phenotypic features of Sjogren’s syndrome among 1,726 registry participants. Arthritis & Rheumatology 2011; 63 (7): 2021-2030. doi: 10.1002/art.30381
14. Coll J, Rives A, Grino MC, Setoain J, Vivancos J et al. Prevalence of Sjogren’s syndrome in autoimmune diseases. Annals of Rheumatic Diseases 1987; 46 (4): 286-289. doi: 10.1136/ ard.46.4.286
15. Cipoletti JF, Buckingham RB, Barnes EL, Peel RL, Mahmood K et al. Sjogren’s syndrome in progressive systemic sclerosis. Annals of Internal Medicine 1977; 87 (5): 535-541. doi: 10.7326/0003-4819-87-5-535
16. Drosos AA, Andonopoulos AP, Costopoulos JS, Stavropoulos ED, Papadimitriou CS et al. Sjogren’s syndrome in progressive systemic sclerosis. Journal of Rheumatology 1988; 15 (6): 965- 968.
17. Rasker JJ, Jayson MI, Jones DE, Matthews R, Burton JL et al. Sjogren’s syndrome in systemic sclerosis. A clinical study of 26 patients. Scandinavian Journal of Rheumatology 1990; 19 (1): 57-65. doi: 10.3109/03009749009092622
18. Ihn H, Yazawa N, Kubo M, Yamane K, Sato S et al. Circulating levels of soluble CD30 are increased in patients with localized scleroderma and correlated with serological and clinical features of the disease. Journal of Rheumatology 2000; 27 (3): 698-702.
19. Marie I, Cordel N, Lenormand B, Hellot MF, Levesque H et al. Clonal T cells in the blood of patients with systemic sclerosis. Archieves of Dermatology 2005; 141 (1): 88-89. doi: 10.1001/ archderm.141.1.88
20. Nagy G, Kovacs J, Zeher M, Czirjak L. Analysis of the oral manifestations of systemic sclerosis. Oral Surgery Oral Medicine Oral Pathology 1994; 77 (2): 141-146. doi: 10.1016/0030-4220(88)90161-2
21. Bell S, Krieg T, Meurer M. Antibodies to Ro/SSA detected by ELISA: correlation with clinical features in systemic scleroderma. British Journal of Dermatology 1989; 121 (1): 35- 41. doi: 10.1111/j.1365-2133.1989.tb01397.x
22. Kobak S, Oksel F, Aksu K, Kabasakal Y. The frequency of sicca symptoms and Sjogren’s syndrome in patients with systemic sclerosis. International Journal of Rheumatic Diseases 2013; 16 (1): 88-92. doi: 10.1111/j.1756-185X.2012.01810.x
23. Baldini C, Mosca M, Della Rossa A, Pepe P, Notarstefano C et al. Overlap of ACA-positive systemic sclerosis and Sjogren’s syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clinical and Experimental Rheumatology 2013; 31 (2): 272-280.
24. Couderc M, Tournadre A, Mathieu S, Pereira B, Soubrier M et al. Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren’s syndrome? Annals of Rheumatic Diseases 2020; 79 (10) :e137. doi: 10.1136/annrheumdis-2019-215777
25. Jelaska A, Korn JH. Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis. Arthritis & Rheumatology 2000; 43 (10): 2230-2239. doi: 10.1002/1529-0131(200010)43:10<2230::AIDANR10>3.0.CO;2-8
26. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nature Reviews Molecular Cell Biology 2002; 3 (5): 349-363. doi: 10.1038/nrm809
27. Manetti M, Neumann E, Milia AF, Tarner IH, Bechi P et al. Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients. Arthritis & Rheumatology 2007; 56 (10): 3442-3447. doi: 10.1002/ art.22940
28. Zhao W, Wang X, Sun KH, Zhou L. Alpha-smooth muscle actin is not a marker of fibrogenic cell activity in skeletal muscle fibrosis. PLoS One 2018; 13 (1): e0191031. doi: 10.1371/ journal.pone.0191031
29. Sisto M, Lorusso L, Ingravallo G, Tamma R, Nico B et al. Reduced myofilament component in primary Sjögren’s syndrome salivary gland myoepithelial cells. Journal of Molecular Histology 2018; 49 (2) :111-121. doi: 10.1007/ s10735-017-9751-2